<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Naltrexone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00704</strong>&#160; (APRD00005, DB05067)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The <span class="caps">FDA</span> has approved naltrexone for the treatment of alcohol dependence. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00704/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00704/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00704.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00704.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00704.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00704.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00704.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00704">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Naltrexon</td><td>German</td><td>INN</td></tr><tr><td>Naltrexona</td><td>Spanish</td><td>INN</td></tr><tr><td>Naltrexone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Naltrexonum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Naltrexone Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000670/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000670/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: RHBRMCOKKKZVRY-ITLPAZOVSA-N</li>
              <li>Monoisotopic Mass: 377.139385968</li>
              <li>Average Mass: 377.862</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000670">DBSALT000670</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abernil</td><td>Medochemie</td></tr><tr><td>Adepend</td><td>AOP Orphan</td></tr><tr><td>Antaxon</td><td>Zambon</td></tr><tr><td>Antaxone</td><td>Pharmazam</td></tr><tr><td>Arrop</td><td>Quimico</td></tr><tr><td>Celupan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Depade</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dependex</td><td>Amomed</td></tr><tr><td>MorViva</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nalerona</td><td>ABL Pharma</td></tr><tr><td>Nalorex</td><td>Bristol-Myers Squibb</td></tr><tr><td>Naltax</td><td>Navana</td></tr><tr><td>Naltrekson</td><td>Wyeth</td></tr><tr><td>Narcoral</td><td>Sirton</td></tr><tr><td>Neksi</td><td>GMP</td></tr><tr><td>Nemexin</td><td>Bristol-Myers Squibb</td></tr><tr><td>Opizone</td><td>Britannia</td></tr><tr><td>Revez</td><td>Soubeiran Chobet</td></tr><tr><td>Revia</td><td>Bristol Myers Squibb</td></tr><tr><td>Trexan</td><td>Du Pont</td></tr><tr><td>Vivitrex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Vivitrol</td><td>Johnson &amp; Johnson</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Embeda</td><td>Naltrexone and Morphine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/appetite-depressants">Appetite Depressants</a></li>
<li><a href="/mesh/narcotic-antagonists">Narcotic Antagonists</a></li>
<li><a href="/mesh/central-nervous-system-depressants">Central Nervous System Depressants</a></li>
<li><a href="/mesh/alcohol-antagonists">Alcohol Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>16590-41-3</td></tr><tr><th>Weight</th><td>Average: 341.4009<br>Monoisotopic: 341.162708229</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>23</sub>NO<sub>4</sub></td></tr><tr><th>InChI Key</th><td>DQCKKXVULJGBQN-XFWGSAIBSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Morphinans</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Morphinans</td></tr><tr><th>Alternative parents</th><td>Benzylisoquinolines; Phenanthrenes and Derivatives; Isoquinolones and Derivatives; Tetralins; Benzofurans; Phenols and Derivatives; Alkyl Aryl Ethers; Cyclohexanols; Cyclohexanones; Piperidines; Tertiary Alcohols; Cyclic Alcohols and Derivatives; Tertiary Amines; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>phenanthrene; isoquinolone; tetralin; benzofuran; cyclohexanone; phenol derivative; cyclohexanol; alkyl aryl ether; piperidine; benzene; tertiary alcohol; cyclic alcohol; tertiary amine; ketone; ether; polyamine; enol; amine; carbonyl group; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.</td></tr><tr><th>Pharmacodynamics</th><td>Naltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, naltrexone will precipitate withdrawal symptomatology.</td></tr><tr><th>Mechanism of action</th><td>Naltrexone is a pure opiate antagonist and has little or no agonist activity. The mechanism of action of naltrexone in alcoholism is not understood; however, involvement of the endogenous opioid system is suggested by preclinical data. Naltrexone is thought to act as a competitive antagonist at mc, &#954;, and &#948; receptors in the CNS, with the highest affintiy for the &#956; receptor. Naltrexone competitively binds to such receptors and may block the effects of endogenous opioids. This leads to the antagonization of most of the subjective and objective effects of opiates, including respiratory depression, miosis, euphoria, and drug craving. The major metabolite of naltrexone, 6-&#946;-naltrexol, is also an opiate antagonist and may contribute to the antagonistic activity of the drug.</td></tr><tr><th>Absorption</th><td>Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1350 L [intravenous administration]</li>
</ul></td></tr><tr><th>Protein binding</th><td>21% bound to plasma proteins over the therapeutic dose range.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. When administered orally, naltrexone undergoes extensive biotransformation and is metabolized to 6 beta-naltrexol (which may contribute to the therapeutic effect) and other minor metabolites.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Naltrexone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00760">6-beta-naltrexol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/781">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Both parent drug and metabolites are excreted primarily by the kidney (53% to 79% of the dose), however, urinary excretion of unchanged naltrexone accounts for less than 2% of an oral dose and fecal excretion is a minor elimination pathway. The renal clearance for naltrexone ranges from 30 to 127 mL/min and suggests that renal elimination is primarily by glomerular filtration.</td></tr><tr><th>Half life</th><td>4 hours for naltrexone and 13 hours for the active metabolite 6 beta-naltrexol.</td></tr><tr><th>Clearance</th><td><ul>
	<li>~ 3.5 L/min [after IV  administration]</li>
</ul></td></tr><tr><th>Toxicity</th><td>In the mouse, rat and guinea pig, the oral LD<sub>50</sub>s were 1,100-1,550 mg/kg; 1,450 mg/kg; and 1,490 mg/kg; respectively. High doses of naltrexone (generally &#8805;1,000 mg/kg) produce salivation, depression/reduced activity, tremors, and convulsions.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Mu-type opioid receptor<br>Gene symbol: OPRM1<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P35372" target="_blank">P35372 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1799971" target="_blank">rs1799971 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A &gt; G</td><td>Those with the AG genotype respond better to therapy (increase number of abstinent days)</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18250251" target="_blank" title="# Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D: An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. doi: 10.1001/archpsyc.65.2.135. &quot;Pubmed&quot;:http://www.ncbi.nlm.nih.gov/pubmed/18250251">18250251 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9769</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9671</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7471</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8685</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8718</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5189</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8336</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5925</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5981</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6656</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9355</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5686</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9354</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8993</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9483</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6324
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.96
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9939
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7174 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.861
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8446
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Alkermes inc</li>
<li>Actavis totowa llc</li>
<li>Barr laboratories inc</li>
<li>Mallinckrodt inc</li>
<li>Sandoz inc</li>
<li>Duramed pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.alkermes.com">Alkermes Inc.</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.cephalon.com">Cephalon Inc.</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li><a href="http://www.duramed.ca">Duramed</a></li>
<li>Eon Labs</li>
<li>Heartland Repack Services LLC</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.kingpharm.com">King Pharmaceuticals Inc.</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Professional Co.</li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>